drugset
Drugs / Sevirumab
last change Aug 1998 re-read 9 days ago

Sevirumab

also known as MSL 109 · EV2-7 · MOAB MSL-109 · Protovir · SDZ MSL-109

Monoclonal antibody

Developed for
cytomegalovirus retinitis · cytomegalovirus infection
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · Sandoz · Facet Biotech · Johns Hopkins Bloomberg School of Public Health · National Center for Research Resources (NCRR)

Trials 6

today NCT00000836 · Ph 2 NCT00001061 · Ph 2 NCT00000135 · Ph 2/3 NCT00004642 · Ph 1/2
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT00002016 — HIV infectious disease, cytomegalovirus retinitis Sandoz Completed No outcome recorded
Phase 1 NCT00002268 — HIV infectious disease, cytomegalovirus infection Sandoz Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00004642 Feb 1995 → ? cytomegalovirus infection National Center for Research Resources (NCRR) Completed No outcome recorded
Phase 22 trials · 1 missed
Phase 2 NCT00000836 ? → Aug 1998 HIV infectious disease, cytomegalovirus retinitis National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT00001061 ? → Mar 1998 HIV infectious disease, cytomegalovirus retinitis National Institute of Allergy and Infectious Diseases (NIAID) Completed Missed primary
Phase 2/31 trial · 1 missed
Phase 2/3 NCT00000135 Sep 1995 → Aug 1996 HIV infectious disease, cytomegalovirus retinitis Johns Hopkins Bloomberg School of Public Health Completed Missed primary

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Sevirumab ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002268 ↗
3

NCT00000836 ↗

NCT00002016 ↗

NCT00001061 ↗
Known as EV2-7 ChEMBL registry synonym — accepted as the source's own label CHEMBL2108881 ↗
Known as MOAB MSL-109 “OBJECTIVES: I. Evaluate the safety, tolerance, and potential efficacy of 3 doses of human anti-cytomegalovirus (CMV) monoclonal antibody SDZ MSL-109 (MOAB MSL-109) in the...” NCT00004642 ↗
Known as MSL 109 “To compare the safety and efficacy of sevirumab (MSL 109; Protovir), human anti-cytomegalovirus (CMV) monoclonal antibody, plus active primary treatment versus placebo plus...” NCT00000836 ↗
2

NCT00004642 ↗

NCT00000135 ↗
Known as Protovir “To compare the safety and efficacy of sevirumab (MSL 109; Protovir), human anti-cytomegalovirus (CMV) monoclonal antibody, plus active primary treatment versus placebo plus...” NCT00000836 ↗
Known as SDZ MSL-109 “OBJECTIVES: I. Evaluate the safety, tolerance, and potential efficacy of 3 doses of human anti-cytomegalovirus (CMV) monoclonal antibody SDZ MSL-109 (MOAB MSL-109) in the...” NCT00004642 ↗
Modality Monoclonal antibody “human anti-cytomegalovirus (CMV) monoclonal antibody” NCT00000836 ↗
Route Intravenous “MSL-109, 60 mg intravenously every 2 weeks” PMID 9400786 ↗ Dec 1997